Top View
- New York City Department of Environmental Protection Community Right-To-Know: List of Hazardous Substances
- Pharmacological Drugs Inducing Ototoxicity, Vestibular Symptoms and Tinnitus: a Reasoned and Updated Guide
- PHOTOSENSITIZING LIST Certain Food/Drugs Do Not Mix with Ultraviolet Light
- Aromatase and Gynecomastia
- Digitoxin Has Specific Properties for Potential Use to Treat Cancer and Inflammatory Diseases
- Long-Term Care Drug Database System: Drugs by NDC Class Code, Drug Code and Name
- Download Supplementary
- Gpi Drug Classification Report
- Risk Assessment Guidance for Superfund Volume I: Human Health Evaluation Manual (Part E, Supplemental Guidance for Dermal Risk Assessment)
- Phenytoin (Kapseals)
- DBL™ Phenytoin Injection BP Solution for Injection
- Early Refill Drug Utilization Review Drugs
- (12) United States Patent (10) Patent No.: US 8,808,751 B2 Cammarano Et Al
- (12) Patent Application Publication (10) Pub. No.: US 2007/0105790 A1 Khodadoust Et Al
- R.E.7. SSS"'5, Transdermally Administered Pharmacologically Or
- Anti-Cancer Agents in Proliferation and Cell Death: the Calcium Connection
- ICD-10-CM TABLE of DRUGS and CHEMICALS 2020
- 01 Stockley's Herbal Medicines Interactions PRELIMS 1
- Na+/K+-Atpase Revisited: on Its Mechanism of Action, Role in Cancer, and Activity Modulation
- Zytiga, INN-Abiraterone Acetate
- Digitoxin 3B37 34-4957/R6 Digitoxin
- CEDIA® Digitoxin Assay
- (12) Patent Application Publication (10) Pub. No.: US 2017/0056347 A1 Glick Et Al
- ( 12 ) United States Patent
- Pharmaceutical Appendix to the Tariff Schedule 2
- Reference Standards Tables New Reference Standards Now
- Supplementary Table 1. All Compounds Causing BLI Enhancement
- WO 2015/200837 Al 30 December 2015 (30.12.2015) P O PCT
- Study Protocol
- DILANTIN - Phenytoin Sodium Capsule, Extended Release Physicians Total Care, Inc
- ICD-10-CM Table of Drugs 2019
- Binding of Digitoxin and Some Related Cardenolides to Human Plasma Proteins
- Cardiac Glycosides Use and the Risk and Mortality of Cancer; Systematic Review and Meta-Analysis of Observational Studies
- Digoxin Use and Estrogen-Sensitive Cancers—Risks and Possible Therapeutic Implications
- Annex I Summary of Product Characteristics
- Digitoxin and Its Analogs As Novel Cancer Therapeutics Hosam a Elbaz1, Todd a Stueckle1,4, William Tse2, Yon Rojanasakul1,5* and Cerasela Zoica Dinu3,6*
- Prediction of Biopharmaceutical Drug Disposition Classification System (BDDCS) by Structural Parameters
- ADAP Quarterly NDC Special Review
- Digoxin Use and Estrogen-Sensitive Cancers: Risks and Possible Therapeutic Implications